potassium inwardly rectifying channel subfamily J member 11Genealiases: BIR · HHF2 · IKATP · KIR6.2 · MODY13 · PHHI
Q-omics provides the consensus-scored KCNJ11 profile across patient tissues and cancer cell-line models. KCNJ11 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, KCNJ11 is differentially expressed in 15, with the highest sampling consensus in COAD. Additionally, KCNJ11 RNA expression shows 18,817 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight BRCA, and COAD as cancer lineages where KCNJ11 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KCNJ11 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KCNJ11 survival associations across molecular data types. KCNJ11 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (4) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KCNJ11 RNA expression–survival associations across cancer types. High KCNJ11 expression shows unfavorable associations in UVM, LIHC and COAD, but favorable associations in BRCA, SKCM and LGG. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for KCNJ11 RNA expression.
This table summarizes KCNJ11 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for KCNJ11. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KCNJ11 shows lower tumor expression in KIRC and higher tumor expression in COAD, LIHC, KIRP, KICH and BRCA. The COAD box plot shows higher KCNJ11 RNA expression in tumor versus normal tissue (log2 FC = +1.430, t-test p < 0.001).
This table shows molecular features associated with KCNJ11 in patient tissues and cancer cell lines. In patient samples, KCNJ11 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, KCNJ11 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Myeloma.
